Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Trimodality therapy for malignant pleural mesothelioma: Results from an EORTC phase II multicentre trial
European Respiratory Journal, Volume 36, No. 6, Year 2010
Notification
URL copied to clipboard!
Description
The European Organisation for Research and Treatment of Cancer (EORTC; protocol 08031) phase II trial investigated the feasibility of trimodality therapy consisting of induction chemotherapy followed by extrapleural pneumonectomy and post-operative radiotherapy in patients with malignant pleural mesothelioma (with a severity of cT3N1M0 or less). Induction chemotherapy consisted of three courses of cisplatin 75 mg·m-2 and pemetrexed 500 mg·m-2. Nonprogressing patients underwent extrapleural pneumonectomy followed by postoperative radiotherapy (54 Gy, 30 fractions). Our primary end-point was "success of treatment" and our secondary end-points were toxicity, and overall and progression-free survival. 59 patients were registered, one of whom was ineligible. Subjects' median age was 57 yrs. The subjects' TNM scores were as follows: cT1, T2 and T3, 36, 16 and six patients, respectively; cN0 and N1, 57 and one patient, respectively. 55 (93%) patients received three cycles of chemotherapy with only mild toxicity. 46 (79%) patients received surgery and 42 (74%) had extrapleural pneumonectomy with a 90-day mortality of 6.5%. Post-operative radiotherapy was completed in 37 (65%) patients. Grade 3-4 toxicity persisted after 90 days in three (5.3%) patients. Median overall survival time was 18.4 months (95% CI 15.6-32.9) and median progression-free survival was 13.9 months (95% CI 10.9-17.2). Only 24 (42%) patients met the definition of success (one-sided 90% CI 0.36-1.00). Although feasible, trimodality therapy in patients with mesothelioma was not completed within the strictly defined timelines of this protocol and adjustments are necessary. Copyright©ERS 2010.
Authors & Co-Authors
van Schil, Paul Emile Y.
Belgium, Edegem
Universitair Ziekenhuis Antwerpen
Baas, Paul
Netherlands, Amsterdam
The Netherlands Cancer Institute
Gaafar, Rabab Mohamed
Egypt, Giza
Cairo University
Maat, Alexander P.W.M.
Netherlands, Rotterdam
Erasmus Universiteit Rotterdam
van de Pol, Marjan
Netherlands, Tilburg
Dr. Bernard Verbeeten Instituut
Hasane, B.
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Klomp, Houke M.
Netherlands, Amsterdam
The Netherlands Cancer Institute
Abdelrahman, Abdelrahman M.
Egypt, Giza
Cairo University
Welche, J.
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
van Meerbeeck, J. P.A.M.
Belgium, Ghent
Universitair Ziekenhuis Gent
Statistics
Citations: 224
Authors: 10
Affiliations: 7
Identifiers
Doi:
10.1183/09031936.00039510
ISSN:
09031936
e-ISSN:
13993003
Research Areas
Cancer
Health System And Policy